These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 26381892)

  • 1. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.
    Torres J; Boyapati RK; Kennedy NA; Louis E; Colombel JF; Satsangi J
    Gastroenterology; 2015 Dec; 149(7):1716-30. PubMed ID: 26381892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.
    Pariente B; Laharie D
    Aliment Pharmacol Ther; 2014 Aug; 40(4):338-53. PubMed ID: 24957164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice.
    Arenas A; Moreta MJ; Ordás I; Fernández-Clotet A; Caballol B; Gallego M; Vara A; Barastegui R; Giner A; Prieto C; Masamunt MC; Candia R; Ricart E
    Gastroenterol Hepatol; 2024; 47(7):673-682. PubMed ID: 37562767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.
    Jones JL; Kaplan GG; Peyrin-Biroulet L; Baidoo L; Devlin S; Melmed GY; Tanyingoh D; Raffals L; Irving P; Kozuch P; Sparrow M; Velayos F; Bressler B; Cheifetz A; Colombel JF; Siegel CA
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2233-40.e1-2; quiz e177-8. PubMed ID: 26142167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease.
    Dohos D; Hanák L; Szakács Z; Kiss S; Párniczky A; Erőss B; Pázmány P; Hegyi P; Sarlós P
    Aliment Pharmacol Ther; 2021 Jan; 53(2):220-233. PubMed ID: 33249621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
    Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
    Mahmoud R; Savelkoul EHJ; Mares W; Goetgebuer R; Witteman BJM; de Koning DB; van Tuyl SAC; Minderhoud I; Lutgens MWMD; Akol-Simsek D; van Schaik FDM; Fidder HH; Jansen JM; van Boeckel PGA; Mahmmod N; Horjus-Talabur Horje CS; Römkens TEH; Colombel JF; Hoentjen F; Jharap B; Oldenburg B;
    Clin Gastroenterol Hepatol; 2023 Mar; 21(3):750-760.e4. PubMed ID: 36055567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
    Balram B; Lubov J; Theoret Y; Afif W; Bitton A; Wild G; Lakatos PL; Bessissow T
    Dig Dis Sci; 2021 May; 66(5):1650-1657. PubMed ID: 32591969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.
    Kennedy NA; Warner B; Johnston EL; Flanders L; Hendy P; Ding NS; Harris R; Fadra AS; Basquill C; Lamb CA; Cameron FL; Murray CD; Parkes M; Gooding I; Ahmad T; Gaya DR; Mann S; Lindsay JO; Gordon J; Satsangi J; Hart A; McCartney S; Irving P; ; Lees CW
    Aliment Pharmacol Ther; 2016 Apr; 43(8):910-923. PubMed ID: 26892328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2024 Apr; 18(4):642-658. PubMed ID: 37943286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?
    Ward MG; Irving PM; Sparrow MP
    World J Gastroenterol; 2015 Oct; 21(40):11331-42. PubMed ID: 26525434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy.
    Gisbert JP; Marín AC; Chaparro M
    Aliment Pharmacol Ther; 2015 Aug; 42(4):391-405. PubMed ID: 26075832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal.
    Ben-Horin S; Chowers Y; Ungar B; Kopylov U; Loebstein R; Weiss B; Eliakim R; Del Tedesco E; Paul S; Roblin X
    Aliment Pharmacol Ther; 2015 Aug; 42(3):356-64. PubMed ID: 26032402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
    Doherty G; Katsanos KH; Burisch J; Allez M; Papamichael K; Stallmach A; Mao R; Berset IP; Gisbert JP; Sebastian S; Kierkus J; Lopetuso L; Szymanska E; Louis E
    J Crohns Colitis; 2018 Jan; 12(1):17-31. PubMed ID: 28981623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review.
    Little DHW; Tabatabavakili S; Shaffer SR; Nguyen GC; Weizman AV; Targownik LE
    Am J Gastroenterol; 2020 Nov; 115(11):1768-1774. PubMed ID: 33156094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy.
    Bots SJ; Kuin S; Ponsioen CY; Gecse KB; Duijvestein M; D'Haens GR; Löwenberg M
    Scand J Gastroenterol; 2019 Mar; 54(3):281-288. PubMed ID: 30907185
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
    Molander P; Färkkilä M; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
    Inflamm Bowel Dis; 2014 Jun; 20(6):1021-8. PubMed ID: 24798636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis.
    Katibian DJ; Solitano V; Polk DB; Nguyen T; Ma C; Syal G; Kobayashi T; Hibi T; Buhl S; Ainsworth MA; Jairath V; Singh S
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):22-33.e6. PubMed ID: 37716619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease.
    Ehrenberg R; Griffith J; Theigs C; McDonald B
    J Manag Care Spec Pharm; 2020 Jun; 26(6):758-765. PubMed ID: 32191593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.